TABLE 1

Demographic and clinical characteristics of 45 H7N9 survivors in China

CharacteristicValuea
All cases (n = 45)T1 (n = 19)T2 (n = 33)T3 (n = 28)
Demographic features
    Males32/45 (71)14/19 (74)25/33 (76)21/28 (71)
    Age
        Median, yr (IQR)50 (36–65)41 (32–73)50 (36–65)52 (34–65)
        ≥60 yr19/45 (42)6/19 (32)14/33 (42)12/28 (43)
    Influenza vaccination0/28 (0)0/12 (0)0/20 (0)0/16 (0)
Complications
    ARDS18/36 (50)12/19 (63)12/24 (50)9/22 (41)
    Respiratory failure18/38 (47)9/19 (47)12/27 (44)10/24 (42)
Treatment and clinical course
    Hospitalization45/45 (100)18/18 (100)32/32 (100)28/28 (100)
        Median (IQR) time, days
            Symptom onset to hospital admission4 (3–6)4 (3–6)4 (3–6)4 (3–6)
            Hospitalization21 (16–29)25 (17–31)24 (15–30)17 (13–27)
    ICU
        Admission14/36 (39)9/17 (53)12/26 (46)6/22 (27)
        Median (IQR) time of stay, days23 (12–26)24 (12–27)24 (12–27)13 (7–25)
Oseltamivir treatment35/37 (95)16/17 (94)26/28 (93)20/22 (91)
Corticosteroid treatment23/38 (61)12/19 (63)16/27 (59)11/21 (52)
Mechanical ventilation12/34 (35)5/17 (29)8/25 (32)7/21 (33)
Follow-up
    Median (IQR) time after symptom onset, days110 (92–122)201 (188–237)375 (362–397)
    Serum sampling77/80 (96)19/19 (100)33/33 (100)25/28 (89)
    PBMC sampling78/80 (98)18/19 (95)32/33 (97)28/28 (100)
Laboratory findings at sample collection time
    Leukopenia0/78 (0)0/19 (0)0/31 (0)0/28 (0)
    Neutropenia0/78 (0)0/19 (0)0/31 (0)0/28 (0)
    Lymphopenia0/78 (0)0/19 (0)0/31 (0)0/28 (0)
    Raised creatine kinase0/66 (0)0/17 (0)0/28 (0)0/21 (0)
    Creatine phosphokinase isoenzymes > 25 U/liter0/58 (0)0/14 (0)0/25 (0)0/19 (0)
  • a Values are numbers (percentages) unless stated otherwise.